{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.6","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Maintenance dose is defined as weekly dose of paricalcitol that results in at least 2 consecutive intact parathyroid hormone (iPTH) values within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)","id":"OG000","title":"End-stage Kidney Disease With Secondary Hyperparathyroidism"}],"paramType":"MEAN","populationDescription":"Participants who achieved maintenance dose of Zemplar (paricalcitol injection)","reportingStatus":"POSTED","timeFrame":"6 months","title":"Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)","type":"PRIMARY","unitOfMeasure":"weeks"}